{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AR-13324+Ophthalmic+Solution+0.02%25&page=2",
    "query": {
      "intervention": "AR-13324 Ophthalmic Solution 0.02%",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AR-13324+Ophthalmic+Solution+0.02%25&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AR-13324+Ophthalmic+Solution+0.02%25&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T14:59:17.642Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06394973",
      "title": "Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "T4090 0.2%",
          "type": "DRUG"
        },
        {
          "name": "T4090 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Rhopressa®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2024-08-05",
      "completion_date": "2024-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 24,
      "location_summary": "Glendale, Arizona • Glendale, California • Inglewood, California + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06394973"
    },
    {
      "nct_id": "NCT07847073",
      "title": "Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma (OAG)",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]",
          "type": "DRUG"
        },
        {
          "name": "Timolol Maleate 0.25% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brett King",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2026-10",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "Bloomington, Indiana",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07847073"
    },
    {
      "nct_id": "NCT02207491",
      "title": "Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 411,
      "start_date": "2014-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-13",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207491"
    },
    {
      "nct_id": "NCT04234932",
      "title": "Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of the Incarnate Word",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-06",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-14",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234932"
    },
    {
      "nct_id": "NCT02057575",
      "title": "Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PG324 Ophthalmic Solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "PG324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil (AR-13324) Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost Ophthalmic Solution 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 23,
      "location_summary": "Artesia, California • Inglewood, California • Newport Beach, California + 20 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057575"
    },
    {
      "nct_id": "NCT01528787",
      "title": "Study of AR-13324 in Patients With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 85,
      "start_date": "2012-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-18",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 11,
      "location_summary": "Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528787"
    },
    {
      "nct_id": "NCT02246764",
      "title": "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "19 Years to 99 Years"
      },
      "enrollment_count": 93,
      "start_date": "2014-09",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246764"
    },
    {
      "nct_id": "NCT06441643",
      "title": "Next Generation Rocklatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AR-17043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "PG043 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "AR-17043 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 426,
      "start_date": "2024-09-04",
      "completion_date": "2025-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 12,
      "location_summary": "Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441643"
    },
    {
      "nct_id": "NCT07325240",
      "title": "24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-21",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07325240"
    },
    {
      "nct_id": "NCT06883123",
      "title": "Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Simbrinza 0.2%-1% Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rocklatan 0.02%-0.005% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Cosopt PF 2%-0.5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prairie Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-14",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-10T14:59:17.642Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06883123"
    }
  ]
}